Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Daiichi Sankyo
Queensland Health
Chinese Patent Office
Deloitte
McKinsey
Boehringer Ingelheim
Cantor Fitzgerald
Dow

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,906,489

« Back to Dashboard

Which drugs does patent 7,906,489 protect, and when does it expire?

Patent 7,906,489 protects DIFICID and is included in one NDA.

This patent has ninety-three patent family members in twenty-five countries.
Summary for Patent: 7,906,489
Title:18-membered macrocycles and analogs thereof
Abstract: The present invention relates generally to the 18-membered macrocyclic antimicrobial agents called Tiacumicins, specifically, OPT-80 (which is composed almost entirely of the R-Tiacumicin B), pharmaceutical compositions comprising OPT-80, and methods using OPT-80. In particular, this compound is a potent drug for the treatment of bacterial infections, specifically C. difficile infections.
Inventor(s): Shue; Youe-Kong (Carlsbad, CA), Hwang; Chan-Kou (San Diego, CA), Chiu; Yu-Hung (San Diego, CA), Romero; Alex (San Diego, CA), Babakhani; Farah (San Diego, CA), Sears; Pamela (San Diego, CA), Okumu; Franklin (Oakland, CA)
Assignee: Optimer Pharmaceuticals, Inc. (San Diego, CA)
Application Number:11/882,219
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,906,489
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 7,906,489

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cubist Pharms Llc DIFICID fidaxomicin TABLET;ORAL 201699-001 May 27, 2011 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF MICROBIAL INFECTIONS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,906,489

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,859,510 Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof ➤ Sign Up
7,863,249 Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof ➤ Sign Up
7,378,508 Polymorphic crystalline forms of tiacumicin B ➤ Sign Up
8,728,796 Tiacumicin production ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
McKesson
Teva
Cantor Fitzgerald
Johnson and Johnson
Julphar
Merck
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.